NCT06496581 2024-12-20Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)UNICANCERPhase 3 Recruiting500 enrolled
NCT02578797 2023-11-09A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc StudyAragon Pharmaceuticals, Inc.Phase 1 Completed45 enrolled